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Abstract
Background: Cardiac inflammation and generation of oxidative stress are known to contribute to trastuzumab
(herceptin) induced cardiac toxicity. Toll-like receptors (TLRs) are a part of the innate immune system and are
involved in cardiac stress reactions. Since TLR4 might play a relevant role in cardiac inflammatory signaling, we
investigated whether or not TLR4 is involved in trastuzumab induced cardiotoxicity.
Methods: Seven days after a single injection of herceptin (2 mg/kg; i.p.), left ventricular pressure volume loops
were measured in HeN compotent (TLR4
+/+) and HeJ mutant (TLR4
-/-) treated with trastuzumab and control mice.
Immunofluorescent staining for monocyte infiltration and analyses of plasma by (ELISAs) for different chemokines
including: MCP-1and tumor necrosis factor-a (TNF-a), Western immunoblotting assay for ICAM-1, and used
troponin I for cardiac injury marker.
Results: Trastuzumab injection resulted in an impairment of left ventricular function in TLR-4 competent (HeN), in
contrast TLR4
-/
- trastuzumab mice showed improved left ventricular function EF%, CO; p < 0.05, attenuation of
mononuclear cell infiltration in TLR4
-/-; p < 0.05 vs.TLR-4 competent (HeN), reduced level of cytokines TNF-a, MCP-
1 and ICAM-1 expression in TLR4
-/-, marked reduction of myocardial troponin-I levels in TLR4-deficient mice. Data
are presented as means ± SE; n = 8 in each group p < 0.05 vs.TLR-4 competent (HeN).
Conclusions: Treatment with trastuzumab induces an inflammatory response that contributes to myocardial tissue
TLR4 mediates chemokine expression (TNF-a, MCP-1and ICAM-1), so in experimental animals TLR4 deficiency
improves left ventricular function and attenuates pathophysiological key mechanisms in trastuzumab induced
cardiomyopathy.
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Background
The human epidermal growth factor receptor (HER)
proteins regulate cell growth, survival, adhesion, migra-
tion, and differentiation functions that are amplified or
weakened in cancer cells. In some cancers, notably some
breast cancers, human epidermal growth factor recep-
tor-2 (HER2) is over-expressed, and, among other
effects, causes breast cells to reproduce uncontrollably
[1]. Trastuzumab is a humanized monoclonal antibody
that binds selectively to the HER2 protein. and has
become a mainstay in the treatment of women with
(HER2) overexpressing breast cancer and in the meta-
static and adjuvant settings this increases the survival of
people with cancer [2]. One of the significant complica-
tions of trastuzumab is its effect on the heart and asso-
ciation with cardiac dysfunction in 2-7% of cases [3]. As
a result, regular cardiac screening with either a MUGA
(MUltiple Gated Acquisition) scan or echocardiography
is commonly undertaken during the trastuzumab treat-
ment period. Approximately 10% of patients are unable
to tolerate this drug because of pre-existing heart pro-
blems; physicians are balancing the risk of recurrent
cancer against the higher risk of death due to cardiac
disease in this population. The risk of cardiomyopathy is
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cline chemotherapy (which itself is associated with car-
diac toxicity) [4,5]
Toll-like receptors (TLRs) have a central role in innate
immunity and inflammation, at least nine types of human
TLRs have recently been identified [6] Among the family
of TLRs, TLR4 has been the focus of particular interest
since its recognition as a receptor for lipopolysaccharide
(LPS; endotoxin) [7,8] It has been shown that active
TLR4 led to expression of nuclear factor-B( N F - B)-
controlled genes for proinflammatory cytokines that are
required for activation of the immune response [9]
Previous study explained the Myocardial tissue TLR4
plays a major role in mediating myocardial injury fol-
lowing cold ischemia and reperfusion through up-regu-
lation of MCP-1, (manuscript) [10]. Furthermore,
increased TLR4 expression was observed in isolated car-
diomyocytes from humans and animals with cardiomyo-
pathies [11]. Growing evidence of a causal link between
TLRs and the development of heart failure has been
derived mostly from studies in knock-out mice support-
ing a relevant role of this receptor family. It had been
shown that TLR4 can modulate LV hypertrophy, myo-
cyte contractility, myocardial ischaemia reperfusion
injury, and plays a role in inflammatory responses
including septic shock syndrome [12]. It is notable that,
cytokine release mediated by activation of the Toll- like
receptors (TLRs ) is believed to be involved in the
pathogenesis of doxorubicin induced cardiotoxicity
[13,14] and are probably also involved in the develop-
ment of doxorubicin induced cardiomyopathy, as has
been shown in TLR2- deficient mice [15]. Identification
of TLR4 ligands and elucidation of the mechanisms of
ligand-TLR4 interaction may lead to the development of
novel approaches for prevention of myocardial injury
associated with trastuzumab treatment.
Aim of the study
This study was done on mouse model to identify the
effect of trastuzumab on TLR4 mutation in on the
heart, leukocyte accumulation in the target area, MCP-
1, ICAM-1, and the role of these chemokines in myocar-
dial injury and leukocyte accumulation after treatment
with trastuzumab.
Methods
Animals
Male C3H/HeJ mice (which have a point mutation in
TLR4, resulting in a complete loss of signaling function)
and C3H/HeN (wild-type) mice, body weight 24-30 g,
acclimatized in a quarantine room for 2 weeks, and
their age range from 8 to 12 weeks. All experiments
were approved by the Animal Care and Research Com-
mittee of the University of Colorado Denver, and this
investigation conforms to the Guide for the Care and
Use of Laboratory Animals (National Research Council,
revised 1996). The animals divided in to 4 groups, con-
trol groups injected with normal saline and other groups
treated with 2 mg/kg trastuzumab in a single injection
intraperitoneal i.p.
Pressure-volume loop and hemodynamic analysis
Pressure-volume loop and hemodynamic analysis was
only planned after 7 days of treated with trastuzumab,
the mouse anesthetized with ketamin in dose of 50 mg/
kg injected intraperitoneal and when the mouse anaes-
thetized, it will be positioned over the heating pad in
supine position and four limbs are taped, in a orienta-
tion that the hind limb in front of operating researcher.
Neck was opened longitudinally and right common car-
otid artery exposed and freed, ligated distally and stay
suture placed proximally, then small opening was made
in artery and size 1 F-micro tipped pressure transducer
catheter (Millar Instruments, Houston, TX, USA) was
inserted into the LV lumen via the right carotid artery
for measurement of LV pressure, volume, function and
related parameters. Then after about 20 minutes of data
recording, the abdomen is opened by right sub costal
incision to reach the inferior vena cava. To acutely
change the cardiac preload, caval occlusion was pro-
duced over a 3-s period using a nonmetallic occluder
applied to the IVC. The data were recorded as a series
of pressure-volume loops.
P van software (Conductance Technologies, San Anto-
nio, TX, and Millar, Houston, TX) was used to analyze
all pressure-volume loop data. Regression analyses of
multiple isochronal pressure-volume loop data were
produced by IVC compression. From the baseline and
IVC compression loops, comprehensive sets of hemody-
namic parameters were calculated. All steady-state and
caval occlusion pressure-volume loops were acquired
with the computer data acquisition system. From these
data we selected the following parameter: LV diameters
were measured at end diastole (LVEDD) and end systole
(LVESD), ejection fraction (EF), heart rate (HR), LV sys-
tolic pressure in the ends of both systole and diastole
(LVESP, LVEDP), Cardiac Output (CO) and the maxi-
mum elasticity (Emax).
Animal scarification
Immediately after finishing the pressure volume loop
measurement, the mouse was sacrificed, starting by
injection of equal volume of thiopental and heparin
intraperotonealy in doses ranging from 100 μlt o2 0 0μl
for each one, after giving good time for the animal to go
into deep anesthesia, the mouse is positioned and taped
and the chest is opened in flap like manner revealing
the heart then a needle of the syringe is introduced into
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plasma analysis. After that the heart is cut from the
great vessels and mediastinum.
Immunofluorescent Staining
Myocardial sections (5 μm thick) were fixed in 4% par-
aformaldehyde, incubated with a rabbit polyclonal anti-
body against PMNs and macrophages, and then
incubated with Cy3-tagged secondary goat anti-rabbit
IgG (imaged on the red channel). Nuclei were stained
with bis-benzimide (DAPI, imaged on the blue chan-
nel), and glycoproteins on cell surfaces with Alexa
488-tagged wheat germ agglutinin (imaged on the
green channel). Microscopy was performed with a
Leica DMRXA digital microscope (Leica Mikroskopie
und Systeme GmbH, Wetzlar, Germany). Immuno-
flourecent antibodies were used to target the macro-
phages and neutrophils.
Plasma for protein assay
The collected blood from each mouse was centrifuged
(in 10000 RPM, for 10 minutes at 4°C) and the yielded
plasma samples of each animal was subjected to protein
assay using enzyme-linked immunosorbent assays (ELI-
SAs) for different chemokines including: MCP-1, tumor
necrosis factor-a (TNF-a), and troponin I.
Western immunoblotting assay
Myocardial tissue was homogenized with a rotor-stator
homogenizer and treated in PBS containing 0.5% Triton
X-100 and a protease inhibitor cocktail. Size fraction of
crude protein (20 μg) was performed by electrophoresis.
After transfer, the membrane was incubated in PBS 5%
nonfat dry milk to block nonspecific binding. The mem-
brane was then incubated for 60 minutes with an anti-
body against ICAM-1, or TLR4 at 1:1000 to 1:2000
dilutions with PBS containing 0.05% Tween 20 and 5%
dry milk. After thorough washes, the membrane was
treated with peroxidase-labeled secondary antibody
(1:5000 dilutions with phosphate-buffered saline con-
taining 0.05% Tween 20 and 5% dry milk) for 45
minutes. Protein bands were developed using enhanced
chemiluminescence technique. Densitometry was per-
formed using a computerized densitometer (Molecular
Dynamics, Sunnyvale, CA).
Statistical analysis
Statistical analysis was performed using the one-way
ANOVA test with a significance of p < 0.05.
Results
TLR4 mutation improves LV function
Selected average parameters from pressure-volume loop
study in the C3H/HeJ (TLR4
-/
- ) and C3H/HeN groups
w e r es h o w ni nt a b l e - 1 ,t h eC 3 H / H e J( T L R 4
-/
-)g r o u p
has significantly better LV function and ventricular elas-
ticity than the wild HeN group in form of EF%, and
Cardiac Output (CO).
TLR4
-/
- attenuated mononuclear cells infiltration
After seven days of a single injection trastuzumab
TLR4-competent (HeN-wild type) hearts exhibited
marked increase in mononuclear cell infiltration com-
pared with TLR4
-/
- (HeJ mutant) hearts which is
demonstrated by immunostaining as in Figure 1.
Reduced level of cytokines TNF-a, MCP-1 and ICAM-1
expression in TLR4
-/
-
To characterize the cardiac inflammatory response due
to the trastuzumab injection, we determined cardiac
cytokines, expression of TNF-a protein, MCP-1and
ICAM-1. led to an increased expression both of them in
WT(C3H/HeN) mice compared to TLR4
-/- (HeJ
mutant) (P < 0.05) Figure 2.
Marked reduction of myocardial troponin-I levels in TLR4-
deficient mice
The level of the troponin-I as cardiac injury marker
show significant reduction in C3H/HeJ strains after
seven days a single dose injection of trastuzumab, and
this reflected that the cardiac injury is more in wild
type, as shown in Figure 3.
Table 1 Selected average parameters from pressure-volume loop study in the C3H/HeN and C3H/HeJ groups
Variables HeN HeJ *P value
Before Tras. After Tras. Before Tras. After Tras.
Heart rate (bpm) 449.67 ± 2.29 392.44 ± 16.47 452 ± 16 448 ± 31 <0.05
End-systolic Volume (uL) 13.42 ± 0.25 45.23 ± 0.42 14.04 ± 0.38 21.28 ± 0.60 <0.05
End-diastolic Volume(uL) 35.25 ± 0.36 63.77 ± 0.51 34.90 ± 0.55 41.40 ± 0.54 <0.05
End-systolic pressure(mmHg) 123.8 ± 0.47 179.35 ± 3.40 122.3 ± 1.03 139.22 ± 1.04 <0.05
End-diastolic pressure(mmHg) 8.2 ± 0.58 97.40 ± 3.53 7.97 ± 0.09 15.28 ± 0.17 <0.05
Ejection Fraction (%) 61.91 ± 8.9 29.06 ± 1.05 63.14 ± 2.17 52.17 ± 2.56 <0.05
Cardiac Output (ml/min) 10.44 ± 4.54 5.03 ± 0.57 11.01 ± 0.30 9.84 ± 0.28 <0.05
*Data are expressed as mean ± SEM; n = 8 in each group P value < 0.05.
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The antitumor functions of trastuzumab are associated
with its ability to modulate signaling through the HER-
2/neu receptor as well as initiate antibody-dependent
cell-mediated cytotoxicity (ADCC) [15]. Recent studies
s u g g e s tt h a tt r a s t u z u m a bd i srupts HER2/HER3 interac-
tions, leading to downregulation of AKT signaling,
which results in decreased cell proliferation [16-18]. At
any stage, the use of trastuzumab reduces recurrence by
about 50% and increases overall survival by about 30%
[19-21] and reduction in the risk for death by about
44% (P < .0001, hazard ratio [HR] = 0.56) [22].
In approximately 4% of patients with trastuzumab
therapy are associated with severe congestive heart fail-
ure, and most of the cardiac toxicity seen with treat-
ment is limited to asymptomatic decreases in the left
ventricular ejection fraction (LVEF); however [23].
In the present study, we tested the hypotheses that
TLR4 mediates mononuclear infiltration and chemokine
expression that response to underlying trastuzumab
treatment. We found that TLR4-competent mice treated
with trastuzumab display severe systolic and diastolic
LV dysfunction, resulting in impaired cardiac output as
measured by the assessment of pressure - volume loops,
while in TLR4
-/
- cardiac output was improved as a
result of enhanced systolic and diastolic performance,
and reduced mononuclear infiltration with significantly
lower levels of TNF-a, MCP-1 and ICAM-1. These
result of correspond to myocardium injury after global
ischemia and reperfusion led to TNF- expression and
other cytokines [24], and is under the control by myo-
cardial TLR4 [25], TNF- may serve as an intermediate
in TLR4-mediated myocardial, including IL-8 and MCP-
1. In myocardiac regional ischemia and reperfusion (I/R)
demonstrate a critical role of TLR4 in myocardial che-
mokines response [26].
The John Cha [27] and his group studies show that
the TLR4 signaling is involved in the myocardial inflam-
matory response after global ischemia/reperfusion and
that TLR4 signaling contributes to cardiac dysfunction
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Figure 1 Immunofluorescent Staining of the myocardial cells for demonstrated mononuclear cells infiltration. Attenuated of infiltration
mononuclear cells (white lines) in HeJ, data are presented as means ± SE; n = 8 in each group, p < 0.05 vs. TLR-4 competent (HeN)
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on myocardial production of TNF-a and IL-1 peptides.
The Kaczorowski and colleagues [28] in which their
data demonstrate that TLR4 signaling is central to both
the systemic and intragraft inflammatory responses that
occur after cold I/R in the setting of organ
transplantation.
I no u re a r l i e rs t u d yw ef o u n dt h a tt h eM y o c a r d i a l
injury after global cold ischemia and perfusion was eval-
uated by serum cardiac troponin-I (cTn-I) as cardiac
marker injury that was decreased levels in HeJ, p < 0.05
vs. TLR4 competent (HeN) [29,30] also we found the
same sequel in the present study the serum levels of
cTn-I in the HeJ mutant (TLR4
-/-) was reduced.
According to our knowlage no study was done that
link between the TLR4 and trastuzumab treatment, so
our data demonstrate for the first time a relevant role of
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Figure 2 level of cytokine (MCP-1, ICAM-1andTNF-a) in myocardial tissue and serum. Blood samples and hearts isolated from C3H/HeN
(TLR4 competent) and C3H/HeJ (TLR4 defective) mice were subjected to single injection of trastuzumab (2 mg/Kg i.p). While control hearts were
subjecting to normal saline i.p. (A) level of TNF-a (B) level of monocyte chemoattractant protein-1 (MCP-1).(C) ICAM-1 was obtained after harvest
heart, Western immunoblotting assay was performed as described in Materials and Methods, markedly reduced ICAM-1 in the He J mutant
(TLR4
-/
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Figure 3 Level of the serum cTn-I in the mice group. Reduced
serum levels cTn-I in the HeJ mutant (TLR4
-/-) group. Data are
expressed as means ± SE; n = 8 in each group; P < 0.05 vs. HeN
treated with trastuzumab.
Yousif and Al-amran BMC Cardiovascular Disorders 2011, 11:62
http://www.biomedcentral.com/1471-2261/11/62
Page 5 of 7TLR4 in the development myocardial injury following
used trastuzumab under experimental conditions.
Further studies using therapeutic interventions such as
pharmacological TLR4 inhibition are required.
Conclusions
This study demonstrates that treated with trastuzumab
induces an inflammatory response that contributes to
myocardial tissue TLR4 as mediates chemokine expres-
sion (TNF-a,M C P - 1 a n dI C A M - 1 ) ,s oi ne x p e r i m e n t a l
animals TLR4 deficiency improves left ventricular func-
tion and attenuates pathophysiological key mechanisms
in herciptin-induced cardiomyopathy.
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